FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and is intended for the treatment of gastrointestinal tract disorders. In case of treatment necessity a pharmaceutical dexlansoprazole-containing composition is introduced to the patient, and it is possible to introduce the said pharmaceutical composition to the patient independently on food consumption or consumed amount of food.
EFFECT: group of inventions makes it possible to improve the flexibility of dosing and increase the patient's adherence to treatment.
16 cl, 7 tbl, 2 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINAL CONTROLLED-RELEASING FORMS OF AZITHROMYCIN | 1995 |
|
RU2130311C1 |
| MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FEBUXOSTAT | 2011 |
|
RU2602188C2 |
| NEW PREPARATION | 2000 |
|
RU2240110C2 |
| ORAL DOSAGE FORMS OF TOFACITINIB WITH CONTINUOUS RELEASE | 2014 |
|
RU2790166C2 |
| PHARMACEUTICAL COMPOSITIONS OF ACOTIAMIDE AND PROTON PUMP INHIBITOR | 2019 |
|
RU2820820C2 |
| CONTROLLED-RELEASE HYDROCODON COMPOSITION | 2001 |
|
RU2253452C2 |
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
| SYSTEMS OF MEDICATION DELIVERY, INCLUDING SOLID SOLUTIONS OF WEAK-BASE MEDICATIONS | 2007 |
|
RU2434630C2 |
| DRUG DELIVERY COMPOSITION | 2010 |
|
RU2589823C2 |
| APPLICATION OF METHYL NALTREXONE FOR TREATING IRRITABLE COLON SYNDROME | 2004 |
|
RU2373936C2 |
